Monocyte Chemoattractant Protein-1 Promoter –2518 Polymorphism May Have an Influence on Clinical Heterogeneity of Bipolar I Disorder in the Korean Population

The aim of this study was to investigate the association between monocyte chemoattractant protein-1 (MCP1) promoter –2518 polymorphism and DSM-IV-based bipolar I disorder (BID) in Korea. Ninety-two patients with BID and 114 healthy controls participated in this study. A polymerase chain reaction-based method was used for genotyping. Genotype and allele distributions in patients with BID were not different from those of the controls, nor were they different according to clinical factors in the patient group. However, the frequency of the A allele (p = 0.028) was significantly different when subdividing the patient group into patients with manic episode versus depressed and mixed episode. The present study suggests that the MCP1 promoter –2518 polymorphism may not confer susceptibility to BID itself, but could have an influence on the clinical heterogeneity of BID, at least in the Korean population.

[1]  A. Serretti,et al.  Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population , 2004, Psychiatry Research.

[2]  J. Hauser,et al.  Association analysis of the insertion/deletion polymorphism in serotonin transporter gene in patients with affective disorder , 2003, European Psychiatry.

[3]  R. Post,et al.  High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder , 2003, Biological Psychiatry.

[4]  S. Yang,et al.  The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  M. Dorf,et al.  Differential Roles of CC Chemokine Ligand 2/Monocyte Chemotactic Protein-1 and CCR2 in the Development of T1 Immunity1 , 2002, The Journal of Immunology.

[6]  R. Elswick,et al.  Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon‐α therapy , 2001, Journal of medical virology.

[7]  Y. Kohno,et al.  Monocyte chemoattractant protein 1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein 1 in Japanese patients with Kawasaki disease. , 2001, Arthritis and rheumatism.

[8]  H. Manji,et al.  The effects of lithium on ex vivo cytokine production , 2001, Biological Psychiatry.

[9]  E. Bosmans,et al.  Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis , 2001, European Neuropsychopharmacology.

[10]  E.C.Hurlock.  Interferons: potential roles in affect. , 2001 .

[11]  C. Kuo,et al.  Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. , 2001, Journal of affective disorders.

[12]  M. Schwarz,et al.  The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. , 2001, Medical hypotheses.

[13]  R. Dantzer.  Cytokine‐Induced Sickness Behavior: Mechanisms and Implications , 2001, Annals of the New York Academy of Sciences.

[14]  M. Loda,et al.  Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1 , 2000, Nature.

[15]  P. Whybrow,et al.  Immune parameters in rapid cycling bipolar patients before and after lithium treatment. , 1999, Journal of psychiatric research.

[16]  B. Rovin,et al.  A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. , 1999, Biochemical and biophysical research communications.

[17]  S. Tsai,et al.  Activation of indices of cell-mediated immunity in bipolar mania , 1999, Biological Psychiatry.

[18]  M. Ackenheil,et al.  Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[19]  B. Leonard,et al.  Depression, stress and immunological activation: the role of cytokines in depressive disorders. , 1998, Life sciences.

[20]  J. Calabrese,et al.  Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. , 1995, Journal of psychiatric research.

[21]  H. Anisman,et al.  Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6 , 1994, Brain Research.

[22]  D. Ledbetter,et al.  Assignment of the human small inducible cytokine A2 gene, SCYA2 (encoding JE or MCP-1), to 17q11.2-12: evolutionary relatedness of cytokines clustered at the same locus. , 1991, Genomics.

[23]  R. C. Young,et al.  A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.

[24]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[25]  E. Hurlock.  Interferons: potential roles in affect. , 2001, Medical hypotheses.

[26]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.